Gold bars to be exempt from tariffs, White House clarifies
SAN DIEGO—Meyer Andrew Hollman, Chief Business Officer of Janux Therapeutics , Inc. (NASDAQ:JANX), recently executed a series of stock transactions, according to a filing with the Securities and Exchange Commission. The transactions come as the stock has shown remarkable performance, gaining over 400% in the past year according to InvestingPro data. On February 3, Hollman sold shares of Janux Therapeutics common stock, amounting to a total value of approximately $140,999. The sale prices ranged from $42.0756 to $43.60 per share, with the stock currently trading near $44.65. Analyst price targets for the company range widely from $25 to $200, reflecting the stock’s notable volatility. Track insider transactions and access more detailed analysis with InvestingPro.
Additionally, Hollman acquired 3,334 shares through an option exercise at a price of $4.21 per share, totaling $14,036. Following these transactions, Hollman holds 82,139 shares directly in the $2.57 billion market cap company. The sales were conducted under a pre-established Rule 10b5-1 trading plan.
In other recent news, Janux Therapeutics continues to gain attention from analysts due to its promising clinical trials. BTIG has affirmed a Buy rating on Janux, emphasizing the competitive positioning of its drug candidate, JANX007, in treating metastatic castration-resistant prostate cancer (mCRPC). The analyst noted the drug’s high benchmark with a 100% greater than 50% PSA response rate that was durable.
Simultaneously, Clear Street initiated coverage on Janux Therapeutics, assigning a Buy rating and a price target of $80. They highlighted the potential of JANX007 to disrupt the approximately $5 billion prostate cancer market. Scotiabank (TSX:BNS) also adjusted its outlook on Janux, increasing the price target to $62 from the previous $42, while maintaining a Sector Perform rating.
Jones Trading raised Janux’s target to $105, maintaining a Buy rating. The firm noted the potential for the treatment to be used in earlier lines of therapy, such as second and third line treatments. TD Cowen reiterated a Buy rating, highlighting the impressive prostate-specific antigen reduction rates, enhanced durability, and minimal toxicity of the ’007 candidate.
These recent developments reflect the growing confidence in Janux’s clinical strategy and the potential of its product pipeline. The company’s ongoing trials and the potential success of JANX007 will be closely monitored by investors and industry observers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.